.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Covington
Chinese Patent Office
Farmers Insurance
Novartis
Johnson and Johnson
Deloitte
Harvard Business School
Julphar
UBS

Generated: September 26, 2017

DrugPatentWatch Database Preview

The Medicines Co Company Profile

« Back to Dashboard

What is the competitive landscape for THE MEDICINES CO, and when can generic versions of THE MEDICINES CO drugs launch?

THE MEDICINES CO has three approved drugs.

There are nineteen US patents protecting THE MEDICINES CO drugs.

There are two hundred and ninety-eight patent family members on THE MEDICINES CO drugs in forty-seven countries.

Summary for Applicant: The Medicines Co

Patents:19
Tradenames:3
Ingredients:3
NDAs:3
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► Subscribe► Subscribe
The Medicines Co
IONSYS
fentanyl hydrochloride
SYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
The Medicines Co
IONSYS
fentanyl hydrochloride
SYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
The Medicines Co
IONSYS
fentanyl hydrochloride
SYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
The Medicines Co
ANGIOMAX
bivalirudin
INJECTABLE;INTRAVENOUS020873-001Dec 15, 2000APRXYesYes► Subscribe► SubscribeY► Subscribe
The Medicines Co
ORBACTIV
oritavancin diphosphate
POWDER;IV (INFUSION)206334-001Aug 6, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
The Medicines Co
ANGIOMAX
bivalirudin
INJECTABLE;INTRAVENOUS020873-001Dec 15, 2000APRXYesYes► Subscribe► SubscribeY► Subscribe
The Medicines Co
IONSYS
fentanyl hydrochloride
SYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
The Medicines Co
IONSYS
fentanyl hydrochloride
SYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for The Medicines Co

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
The Medicines Co
ANGIOMAX
bivalirudin
INJECTABLE;INTRAVENOUS020873-001Dec 15, 2000► Subscribe► Subscribe
The Medicines Co
IONSYS
fentanyl hydrochloride
SYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006► Subscribe► Subscribe
The Medicines Co
IONSYS
fentanyl hydrochloride
SYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006► Subscribe► Subscribe
The Medicines Co
IONSYS
fentanyl hydrochloride
SYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006► Subscribe► Subscribe
The Medicines Co
IONSYS
fentanyl hydrochloride
SYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006► Subscribe► Subscribe
The Medicines Co
IONSYS
fentanyl hydrochloride
SYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006► Subscribe► Subscribe
The Medicines Co
IONSYS
fentanyl hydrochloride
SYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006► Subscribe► Subscribe
The Medicines Co
IONSYS
fentanyl hydrochloride
SYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006► Subscribe► Subscribe
The Medicines Co
IONSYS
fentanyl hydrochloride
SYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006► Subscribe► Subscribe
The Medicines Co
IONSYS
fentanyl hydrochloride
SYSTEM;IONTOPHORESIS, TRANSDERMAL021338-001May 22, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for THE MEDICINES CO drugs

Drugname Dosage Strength Tradename Submissiondate
bivalirudin
For Injection250 mg/vial
ANGIOMAX
9/1/2009

Non-Orange Book Patents for The Medicines Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,090,095 Electrotransport delivery device► Subscribe
9,645,179Self-test for analgesic product► Subscribe
9,731,121Switch validation circuit and method► Subscribe
7,054,683Methods of electrotransport drug delivery► Subscribe
5,952,466 Reductive alkylation of glycopeptide antibiotics► Subscribe
5,977,062 Glycopeptide antibiotic derivatives► Subscribe
6,317,629 Iontophoretic drug delivery apparatus► Subscribe
5,843,889 Glycopeptide antibiotic derivatives► Subscribe
6,505,069 Electrochemically reactive cathodes for an electrotransport device► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for The Medicines Co Drugs

Country Document Number Estimated Expiration
Canada2200602► Subscribe
Netherlands1003274► Subscribe
South Korea100388867► Subscribe
Japan2002513596► Subscribe
Japan5782615► Subscribe
Finland20050513► Subscribe
Australia2009285564► Subscribe
Finland950374► Subscribe
Malaysia128335► Subscribe
Peru40996► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for The Medicines Co Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00521Netherlands► SubscribePRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006
2016000075Germany► SubscribePRODUCT NAME: ORITAVANCIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/989 20150319
0653Netherlands► SubscribePRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906
2006000022Germany► SubscribePRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126
00522Netherlands► SubscribePRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006
C/GB06/022United Kingdom► SubscribePRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124
2011000009Germany► SubscribePRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
0834Netherlands► SubscribePRODUCT NAME: ORITAVANCIN; REGISTRATION NO/DATE: EU/1/15/989 20150323
2016 00044Denmark► SubscribePRODUCT NAME: ORITAVANCIN OG/ELLER FARMACEUTISKE SALTE HERAF, HERUNDER DIFOSFATSALTE; REG. NO/DATE: EU/1/15/989 20150323
C/GB04/035United Kingdom► SubscribePRODUCT NAME: H-(D-PHE)-PRO-ARG-PRO-(GLY)4-ASN-GLY-ASP-PHE-GLU-GLU-ILE-PRO-GLU-GLU-TYR-LEU-OH, OPTIONALLY IN THE FORM OF ITS PHARMACEUTICALLY ACCEPTABLE SALT (BIVALIRUDIN); REGISTERED: UK EU/1/04/289/001 20040920
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Boehringer Ingelheim
Queensland Health
Julphar
Cerilliant
Cantor Fitzgerald
AstraZeneca
Moodys
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot